Drug intelligence / Profile preview

ALECSAT + temozolomide

Development stage: Unknown
Lead developer: CytoVac
Modality: Adoptive Cell Transfer → Cell Therapies, Small Molecules
Administration: Intravenous, Oral

Overview

ALECSAT + temozolomide is a combination therapy consisting of Autologous Lymphoid Effector Cells Specific Against Tumor (ALECSAT), an immune cell therapy, and temozolomide, a chemotherapy drug. This combination is being investigated primarily for the treatment of glioblastoma, a type of malignant brain tumor. ALECSAT works by enhancing the patient's immune response against cancer cells through immunologic cytotoxicity, while temozolomide damages the DNA of cancer cells, preventing them from dividing.

Other names: Autologous Lymphoid Effector Cells Specific Against Tumour-Cells + temozolomide

Targets

DNAMAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on ALECSAT + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALECSAT + temozolomide.

Explore the full profile